Drug Testers Fight Cannabis Rescheduling

The drug testing industry is actively lobbying to prevent the U.S. government from rescheduling cannabis, a move that could significantly impact their business model and the reliability of current testing methods. Industry groups argue that rescheduling could lead to unreliable tests and potentially increase workplace safety risks. Key Highlights: Drug testing companies are raising concerns…

Read More

Trulieve to Make History on NYSE

Trulieve Cannabis Corp. is poised to make history as the first U.S. cannabis company to be listed on the New York Stock Exchange (NYSE), a significant milestone that could reshape the perception and accessibility of the burgeoning industry. Trulieve will be the first U.S. cannabis company to trade on the NYSE. The listing represents a…

Read More

Trulieve NYSE Debut Amidst Cannabis Legal Hurdles

Trulieve Cannabis Corp. made history today by becoming the first multi-state operator to debut on the New York Stock Exchange (NYSE), a significant milestone for the U.S. cannabis industry. This momentous occasion, however, unfolds against a backdrop of increasing legal scrutiny and potential federal rescheduling of cannabis, casting a complex shadow over the industry’s future…

Read More

Trulieve Triumphs: First Cannabis Co. on NYSE!

Trulieve Cannabis Corp. has shattered barriers by becoming the first U.S. cannabis company to achieve a listing on the New York Stock Exchange (NYSE), a monumental step for the industry. Key Highlights: Trulieve is the first U.S. cannabis company to list on the NYSE. This listing signifies growing mainstream acceptance and financial viability of the…

Read More

Feds Shift on Marijuana: What’s Next for Medical Use?

The federal government’s evolving stance on medical marijuana signals a significant shift, potentially reshaping research, patient access, and state-level regulations across the nation. This change reflects a growing acknowledgment of cannabis’s therapeutic potential and a move toward harmonizing federal policy with public opinion and scientific inquiry. Key Highlights: Federal reclassification of marijuana could spur more…

Read More

Tweed Returns to Germany: Canopy Growth Launches MTL Cannabis

Canopy Growth has officially relaunched its renowned Tweed brand in the German market, introducing a new lineup of cannabis strains under the MTL Cannabis banner. This strategic move marks Canopy Growth’s first international product release following its acquisition of MTL Cannabis, signaling a significant expansion of its global footprint and commitment to providing high-quality cannabis…

Read More

DEA Registration: Cresco Labs Secures Medical Cannabis Facilities

Cresco Labs has successfully registered its medical cannabis facilities with the U.S. Drug Enforcement Administration (DEA), a significant step that aligns with the federal government’s proposed rescheduling of marijuana. This move is crucial for research and development, potentially paving the way for broader accessibility and scientific exploration of cannabis-based therapies. The registration process involves stringent…

Read More

Cannabis Tax Overhaul: Billions Unlocked by Federal Order?

A recent federal directive is poised to dramatically alter how cannabis businesses are taxed, potentially unlocking billions in previously inaccessible revenue and marking a significant shift from the industry’s long-standing classification alongside drug traffickers. Key Highlights: A new federal order could change how cannabis companies are taxed. This shift aims to unlock billions in potential…

Read More

Youngkin Vetoes Sales Bill, DOT Sticks to Drug Testing

Virginia Governor Glenn Youngkin has vetoed a bill that would have expanded sales, stating that the Department of Transportation will maintain its current policy on drug testing for transport employees. Key Highlights: Governor Youngkin exercised his veto power on a bill concerning sales expansion. The Department of Transportation will continue its existing drug testing protocols…

Read More

Cannabis 2026: Market Shifts & Regulatory Tides

The cannabis industry is poised for significant evolution in 2026, driven by shifting consumer preferences, emerging markets, and the ongoing debate surrounding federal legalization in the United States. Stakeholders are bracing for a landscape shaped by increased competition, evolving product innovation, and a complex regulatory environment. Key Highlights: Expansion into new product categories beyond traditional…

Read More